Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $23 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Laura Chico reiterates an Outperform rating on Travere Therapeutics (NASDAQ:TVTX) and maintains a $23 price target.
June 21, 2023 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico reiterates an Outperform rating on Travere Therapeutics and maintains a $23 price target.
The reiteration of the Outperform rating and maintenance of the $23 price target by Wedbush analyst Laura Chico indicates a positive outlook for Travere Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100